Cyclacel Pharmaceuticals Stock (NASDAQ: CYCC) stock price, news, charts, stock research, profile.
Open | $1.890 |
Close | $1.780 |
Volume / Avg. | 10.391K / 45.838K |
Day Range | 1.772 - 1.950 |
52 Wk Range | 1.520 - 13.200 |
Market Cap | $2.399M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 40 |
Short Interest | 1.95% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Cyclacel Pharmaceuticals (NASDAQ: CYCC) through any online brokerage.
Other companies in Cyclacel Pharmaceuticals’s space includes: Dermata Therapeutics (NASDAQ:DRMA), NeuBase Therapeutics (NASDAQ:NBSE), Bone Biologics (NASDAQ:BBLG), Quoin Pharmaceuticals (NASDAQ:QNRX) and Qualigen Therapeutics (NASDAQ:QLGN).
The latest price target for Cyclacel Pharmaceuticals (NASDAQ: CYCC) was reported by Brookline Capital on Tuesday, December 19, 2023. The analyst firm set a price target for 0.00 expecting CYCC to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
The stock price for Cyclacel Pharmaceuticals (NASDAQ: CYCC) is $1.82 last updated April 18, 2024 at 4:48 PM EDT.
There are no upcoming dividends for Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.